IIM
MCID: IDP024
MIFTS: 50

Idiopathic Inflammatory Myopathy (IIM)

Categories: Bone diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Idiopathic Inflammatory Myopathy

MalaCards integrated aliases for Idiopathic Inflammatory Myopathy:

Name: Idiopathic Inflammatory Myopathy 53 25
Idiopathic Inflammatory Myopathies 25 73
Idiopathic Inflammatory Myositis 53 25
Myositis 53 73
Idiopathic Inflammatory Myopathy, Familial 53
Myopathies Idiopathic Inflammatory 55
Inflammatory Myopathy, Idiopathic 25
Iim 53
Imm 53

Classifications:



External Ids:

Summaries for Idiopathic Inflammatory Myopathy

NIH Rare Diseases : 53 Idiopathic inflammatory myopathy refers to a group of conditions that affect the skeletal muscles (muscles used for movement). Although the condition can be diagnosed at any age, idiopathic inflammatory myopathy most commonly occurs in adults between ages 40 and 60 years or in children between ages 5 and 15 years. Signs and symptoms of the condition include muscle weakness, joint pain and fatigue. There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis, which are each associated with unique features. As the name suggests, the cause of the condition is currently unknown (idiopathic). However, researchers suspect that it may occur due to a combination of genetic and environmental factors. Treatment is supportive and based on the signs and symptoms present in each person.

MalaCards based summary : Idiopathic Inflammatory Myopathy, also known as idiopathic inflammatory myopathies, is related to myositis and histoplasmosis, and has symptoms including muscle weakness, myoclonus and back pain. An important gene associated with Idiopathic Inflammatory Myopathy is TRIM21 (Tripartite Motif Containing 21), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Simvastatin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, lung and testes, and related phenotype is Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers.

Genetics Home Reference : 25 Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age.

Wikipedia : 76 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Related Diseases for Idiopathic Inflammatory Myopathy

Diseases related to Idiopathic Inflammatory Myopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 450)
# Related Disease Score Top Affiliating Genes
1 myositis 30.7 AARS HLA-DRB1 TRIM21
2 histoplasmosis 29.7 HLA-B HLA-DRB1
3 uveitis 29.6 HLA-B IL1A
4 rheumatoid arthritis 29.5 HLA-B HLA-DRB1 IL1A
5 connective tissue disease 29.5 HLA-DRB1 IL1A
6 graft-versus-host disease 29.5 HLA-B HLA-DRB1 IL1A
7 microscopic polyangiitis 29.5 HLA-B HLA-DRB1
8 rheumatic heart disease 29.4 HLA-B HLA-DRB1
9 cholangitis 29.4 HLA-B HLA-DRB1
10 rheumatic disease 29.3 HLA-B HLA-DRB1 TRIM21
11 diabetes mellitus 29.0 HLA-B HLA-DRB1 IL1A
12 psoriatic arthritis 29.0 HLA-B HLA-DRB1 IL1A
13 malaria 28.8 HLA-B HLA-DRB1 IL1A
14 inflammatory bowel disease 28.8 HLA-B HLA-DRB1 IL1A
15 congenital disorder of glycosylation, type iim 12.6
16 myositis ossificans 12.5
17 focal myositis 12.3
18 myositis fibrosa 12.3
19 fibrodysplasia ossificans progressiva 12.3
20 viral myositis 12.3
21 bacterial myositis 12.3
22 infective myositis 12.2
23 fungal myositis 12.2
24 idiopathic eosinophilic myositis 12.2
25 overlap myositis 12.2
26 granulomatous myositis 12.2
27 juvenile overlap myositis 12.1
28 slc35a2-congenital disorder of glycosylation 11.9
29 childhood type dermatomyositis 11.6
30 necrotizing autoimmune myopathy 11.5
31 orbital plasma cell granuloma 11.4
32 welander distal myopathy, swedish type 11.3
33 foot drop 11.3
34 proteasome-associated autoinflammatory syndrome 3 11.1
35 juvenile polymyositis 11.1
36 xanthinuria, type ii 11.0
37 osseous heteroplasia, progressive 11.0
38 epidemic pleurodynia 11.0
39 myopathy 10.9
40 macrophagic myofasciitis 10.6
41 lung disease 10.4
42 interstitial lung disease 10.4
43 dermatomyositis 10.4
44 fasciitis 10.3
45 muscle disorders 10.3
46 dysphagia 10.2
47 enthesopathy 10.2
48 polymyositis 10.2
49 influenza 10.2
50 myasthenia gravis 10.2

Graphical network of the top 20 diseases related to Idiopathic Inflammatory Myopathy:



Diseases related to Idiopathic Inflammatory Myopathy

Symptoms & Phenotypes for Idiopathic Inflammatory Myopathy

UMLS symptoms related to Idiopathic Inflammatory Myopathy:


muscle weakness, myoclonus, back pain, myalgia, torticollis, sciatica, muscle rigidity, muscle cramp, muscle spasticity

GenomeRNAi Phenotypes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers GR00195-A-3 8.62 IL1A TRIM21

Drugs & Therapeutics for Idiopathic Inflammatory Myopathy

Drugs for Idiopathic Inflammatory Myopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
2 tannic acid Approved Phase 4,Phase 2,Phase 3
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 94-09-7, 1994-09-7 2337
5
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
6
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
7
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
8
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
9 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Not Applicable
10 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
11 Calcium, Dietary Phase 4,Phase 2,Early Phase 1,Not Applicable
12 Rosuvastatin Calcium Phase 4,Not Applicable 147098-20-2
13 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
14 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Reverse Transcriptase Inhibitors Phase 4,Not Applicable
18 Anti-HIV Agents Phase 4,Not Applicable
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
21 Anti-Retroviral Agents Phase 4,Not Applicable
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
28 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Vaccines Phase 4,Phase 3,Not Applicable
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 beta-endorphin Phase 4,Phase 2
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Melanocyte-Stimulating Hormones Phase 4,Phase 2
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Adrenocorticotropic Hormone Phase 4,Phase 2
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Atorvastatin Calcium Phase 4,Not Applicable 134523-03-8
38
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
39
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1 302-25-0
40
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
41
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
42
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
43
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1 2921-57-5
44
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
45
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
46
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
47
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
48
Infliximab Approved Phase 2, Phase 3 170277-31-3
49
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 46835353 6436030 5284616
50
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
6 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
7 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
8 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
9 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
10 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
11 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
12 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
13 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
14 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
15 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
16 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
17 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
18 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
19 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
20 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
21 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
22 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
23 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
24 A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection Completed NCT01527110 Phase 3 Intravenous (IV) zanamivir
25 A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children Completed NCT01218308 Phase 3
26 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
27 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
28 L-Citrulline in Patients With Post-Polio Syndrome Completed NCT02801071 Phase 3 15g L-citrulline daily p.o.;Placebo
29 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
30 Belimumab in Idiopathic Inflammatory Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
31 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
32 Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis Recruiting NCT03686969 Phase 3 Octanorm
33 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms Recruiting NCT03653364 Phase 3 Baloxavir Marboxil
34 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms Recruiting NCT03629184 Phase 3 Baloxavir Marboxil;Oseltamivir
35 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting NCT03486873 Phase 3 Standard of Care (SOC)
36 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Recruiting NCT03813160 Phase 3 Lenabasum 20 mg;Lenabasum 5 mg;Placebo
37 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Recruiting NCT03381196 Phase 3 Pimodivir 600 mg;Placebo
38 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection Recruiting NCT03376321 Phase 3 Pimodivir 600 mg;Placebo
39 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Active, not recruiting NCT02728752 Phase 3 Octagam 10%
40 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Active, not recruiting NCT03312634 Phase 3 Palovarotene
41 Statins And Cirrhosis: Reducing Events of Decompensation Not yet recruiting NCT03654053 Phase 3 Placebo Oral Tablet;Simvastatin 40mg
42 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease Not yet recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
43 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
44 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
45 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
46 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
47 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
48 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
49 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
50 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin

Search NIH Clinical Center for Idiopathic Inflammatory Myopathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Idiopathic Inflammatory Myopathy

Anatomical Context for Idiopathic Inflammatory Myopathy

MalaCards organs/tissues related to Idiopathic Inflammatory Myopathy:

41
Skeletal Muscle, Lung, Testes, Bone, T Cells, B Cells, Heart

Publications for Idiopathic Inflammatory Myopathy

Articles related to Idiopathic Inflammatory Myopathy:

(show top 50) (show all 508)
# Title Authors Year
1
Venous thromboembolic events in idiopathic inflammatory myopathy - occurrence and relation to disease onset. ( 29579357 )
2018
2
The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. ( 29541951 )
2018
3
Correction: <i>Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study</i>. ( 29650643 )
2018
4
Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. ( 29429407 )
2018
5
Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody. ( 29552370 )
2018
6
Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al. ( 29513937 )
2018
7
Early detection of myocardial involvement by T<sub>1</sub>mapping of cardiac MRI in idiopathic inflammatory myopathy. ( 29328539 )
2018
8
Idiopathic Inflammatory Myopathy and Antisynthetase Syndrome: Early Diagnosis by 99mTc-HDP Bone Scintigraphy. ( 30325823 )
2018
9
Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy. ( 30116555 )
2018
10
Rapid Progression of Heart Failure in a Patient with Idiopathic Inflammatory Myopathy. ( 30221193 )
2018
11
Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. ( 30378704 )
2018
12
CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. ( 30508148 )
2018
13
Exploring Road of Classification Criteria for Idiopathic Inflammatory Myopathy. ( 30511678 )
2018
14
Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. ( 30392161 )
2018
15
Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. ( 30208379 )
2018
16
Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. ( 29532710 )
2018
17
Correction to: identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. ( 29642946 )
2018
18
Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. ( 28435082 )
2018
19
Relevance of ultrasonography in assessing disease activity in patients with idiopathic inflammatory myopathies. ( 28782262 )
2018
20
Idiopathic inflammatory myopathies overlapping with systemic diseases. ( 29154752 )
2018
21
2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why? ( 29170201 )
2018
22
Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice. ( 29237619 )
2018
23
Response to: '2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya. ( 29247124 )
2018
24
Opportunistic infections in patients with idiopathic inflammatory myopathies. ( 29314762 )
2018
25
Response to: 'Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice' by Hočevar et al. ( 29317406 )
2018
26
Analysis of anti-melanoma differentiation-associated gene 5 antibody in Hong Kong Chinese patients with idiopathic inflammatory myopathies: diagnostic utility and clinical correlations. ( 29380533 )
2018
27
Does Pulmonary Involvement Play a Role in Right Ventricular Dysfunction of Patients with Idiopathic Inflammatory Myopathies? ( 29419451 )
2018
28
Revisiting Pathological Classification Criteria for Adult Idiopathic Inflammatory Myopathies: In-Depth Analysis of Muscle Biopsies and Correlation Between Pathological Diagnosis and Clinical Manifestations. ( 29522204 )
2018
29
Differential Clinical Associations of Anti-Nuclear Matrix Protein 2 Autoantibodies in Patients With Idiopathic Inflammatory Myopathies. ( 29534337 )
2018
30
Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies. ( 29538753 )
2018
31
Diagnostic Approach to Cardiac Involvement in Idiopathic Inflammatory Myopathies. ( 29563381 )
2018
32
Treatment of adult idiopathic inflammatory myopathies with conventional immunosuppressive drugs : Results of a retrospective study. ( 29713867 )
2018
33
Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies. ( 29761224 )
2018
34
Idiopathic inflammatory myopathies in adults: A comparative study of Bohan and Peter and European Neuromuscular Center 2004 criteria. ( 29766941 )
2018
35
Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study. ( 29971584 )
2018
36
The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. ( 29976041 )
2018
37
The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies. ( 29976235 )
2018
38
The Risk of Ischemic and Haemorrhagic Stroke in Idiopathic Inflammatory Myopathies: a Swedish population-based cohort study. ( 29999244 )
2018
39
Juvenile Idiopathic Inflammatory Myopathies. ( 30031496 )
2018
40
Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies. ( 30033499 )
2018
41
The incidence of idiopathic inflammatory myopathies in the adult Slovenian population. ( 30073460 )
2018
42
Correction: European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. ( 30097512 )
2018
43
Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. ( 30138132 )
2018
44
Targeted capture sequencing identifies novel genetic variations in Chinese patients with idiopathic inflammatory myopathies. ( 30146738 )
2018
45
Long-term follow-up of 76 Iranian patients with idiopathic inflammatory myopathies. ( 30146744 )
2018
46
Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. ( 30169697 )
2018
47
Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study. ( 30219767 )
2018
48
The role of imaging in evaluating patients with idiopathic inflammatory myopathies. ( 30296982 )
2018
49
Clinical phenotype, autoantibody profile and HLA-DR-type in Vietnamese patients with idiopathic inflammatory myopathies. ( 30371850 )
2018
50
Anti-TIF1γ antibody and the expression of TIF1γ in idiopathic inflammatory myopathies. ( 30398003 )
2018

Variations for Idiopathic Inflammatory Myopathy

Expression for Idiopathic Inflammatory Myopathy

Search GEO for disease gene expression data for Idiopathic Inflammatory Myopathy.

Pathways for Idiopathic Inflammatory Myopathy

GO Terms for Idiopathic Inflammatory Myopathy

Cellular components related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 8.96 HLA-B HLA-DRB1
2 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.62 HLA-B HLA-DRB1

Biological processes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.33 HLA-B HLA-DRB1 IL1A
2 antigen processing and presentation GO:0019882 8.96 HLA-B HLA-DRB1
3 interferon-gamma-mediated signaling pathway GO:0060333 8.8 HLA-B HLA-DRB1 TRIM21

Molecular functions related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.62 HLA-B HLA-DRB1

Sources for Idiopathic Inflammatory Myopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....